Early Detection: Disease Detection & Diagnostics
Early detection - of diagnosis of disease or of treatment responsiveness - is the single most important
indicator of positive health outcomes.
Canary’s Detect disease diagnostics platform can deliver critical disease detection and diagnostic information to physicians, primary care providers, and patients, enabling the development of expedited treatment, faster and more successful disease treatments and recoveries, and improved patient health and outcomes.
Analyzing the VOC and metabolic profile of in vitro cancer cells provides an effective alternative to invasive cancer diagnostics and bypasses many confounding factors associated with human samples. For many blood based liquid biopsies requires detection of tumor DNA. Unfortunately, up to 40% of cancerous tumors do not shed DNA fragments into the blood stream for genetic testing.
Our system detects most tumors at their inception when the begin to metabolize; we can find tumors and localize them to organ sites where liquid biopsies cannot.
Early diagnosis of lung cancer continues to be a major clinical challenge and the opportunity for products that can successfully detect the disease early enough to boost survival rate is massive. The five-year survival rate for lung cancer remains a dismal 17.7%, a rate that improved only by a few percentage points since the 1970s, largely because most cases are still diagnosed in late stages. The disease is also common, being the second-most frequently diagnosed cancer in the US and the most diagnosed kind in China, where smoking is on the rise among young adults.
Early Cancer screening at checkups is the single biggest diagnostic opportunity in recent history.
Two thirds of cancers caught early are curable.
...of those caught late, 80% are fatal.
Early detection improves patient outcomes by 5-10x versus late stage disease detection
